Evaluation of the mechanism underlying melatonin action in cholestatic liver disease treatment via network pharmacology, molecular docking, and in vivo experiments
Fig 5
Target-pathway network of melatonin for treating cholestatic liver disease.
Green circles denote the key targets of melatonin for treating cholestatic liver disease, blue circles represent the key signaling pathways involved, and each edge indicates a target-pathway association.